Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis

Nature Genetics

Volumn 45, Issue 7, 2013, Pages 756-766

  Rahrmann, Eric P ^a,b,c   Watson, Adrienne L ^a,b,c   Keng, Vincent W ^d   Choi, Kwangmin ^e   Moriarity, Branden S ^a,b,c   Beckmann, Dominic A ^a,c   Wolf, Natalie K ^b   Sarver, Aaron ^a   Collins, Margaret H ^e   Moertel, Christopher L ^b,c   Wallace, Margaret R ^f   Gel, Bernat ^g   Serra, Eduard ^g   Ratner, Nancy ^e   Largaespada, David A ^a,b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^e CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^f UNIVERSITY OF FLORIDA   (United States)

^g Institut de Medicina Predictiva i Personalitzada del Cancer IMPPC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FORKHEAD TRANSCRIPTION FACTOR; GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; TRANSCRIPTION FACTOR FOXR2; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMMON INSERTION SITE ANALYSIS; CONTROLLED STUDY; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SCREENING; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MOUSE; MUTAGENESIS; NEUROFIBROMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTO ONCOGENE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TRANSPOSON;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA MUTATIONAL ANALYSIS; DNA TRANSPOSABLE ELEMENTS; GENES, NEOPLASM; GENETIC ASSOCIATION STUDIES; GENETIC TESTING; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; NERVE SHEATH NEOPLASMS; NEUROFIBROMA; SIGNAL TRANSDUCTION;

MUS;

EID: 84879690769     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.2641     Document Type: Article

References (91)

1. Ducatman, B.S., Scheithauer, B.W., Piepgras, D.G., Reiman, H.M. & Ilstrup, D.M. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 57, 2006-2021 (1986).
2. Evans, D.G. et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J. Med. Genet. 39, 311-314 (2002).
3. Watson, M.A. et al. Gene expression profiling reveals unique molecular subtypes of neurofibromatosis type I-associated and sporadic malignant peripheral nerve sheath tumors. Brain Pathol. 14, 297-303 (2004).
4. Holtkamp, N. et al. Subclassification of nerve sheath tumors by gene expression profiling. Brain Pathol. 14, 258-264 (2004).
5. Miller, S.J. et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res. 66, 2584-2591 (2006).
6. Zou, C. et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann. Surg. 249, 1014-1022 (2009).
7. Messiaen, L.M. et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum. Mutat. 15, 541-555 (2000).
8. Leppig, K.A. et al. Familial neurofibromatosis 1 microdeletions: cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromata. Am. J. Med. Genet. 73, 197-204 (1997).
9. De Raedt, T. et al. Elevated risk for MPNST in NF1 microdeletion patients. Am. J. Hum. Genet. 72, 1288-1292 (2003).
10. Ballester, R. et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 63, 851-859 (1990).
11. Sherman, L.S., Atit, R., Rosenbaum, T., Cox, A.D. & Ratner, N. Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts. J. Biol. Chem. 275, 30740 (2000).
12. Basu, T.N. et al. Aberrant regulation of Ras proteins in malignant-tumor cells from type-1 neurofibromatosis patients. Nature 356, 713-715 (1992).
13. Cichowski, K. & Jacks, T. NF1 tumor suppressor gene function: narrowing the GAP. Cell 104, 593-604 (2001).
14. Forus, A. et al. Comparative genomic hybridization analysis of human sarcomas: I. occurrence of genomic imbalances and identification of a novel major amplicon at 1q21-q22 in soft tissue sarcomas. Genes Chromosom. Cancer 14, 8-14 (1995).
15. Lothe, R.A. et al. Gain of 17q24-qter detected by comparative genomic hybridization in malignant tumors from patients with von Recklinghausen's neurofibromatosis. Cancer Res. 56, 4778-4781 (1996).
16. Mechtersheimer, G. et al. Analysis of chromosomal imbalances in sporadic and NF1-associated peripheral nerve sheath tumors by comparative genomic hybridization. Genes Chromosom. Cancer 25, 362-369 (1999).
17. Mertens, F. et al. Cytogenetic findings in malignant peripheral nerve sheath tumors. Int. J. Cancer 61, 793-798 (1995).
18. Plaat, B.E. et al. Computer-assisted cytogenetic analysis of 51 malignant peripheral-nerve-sheath tumors: sporadic vs. neurofibromatosis-type-1- associated malignant schwannomas. Int. J. Cancer 83, 171-178 (1999).
19. Schmidt, H. et al. Genomic imbalances of 7p and 17q in malignant peripheral nerve sheath tumors are clinically relevant. Genes Chromosom. Cancer 25, 205-211 (1999).
20. Schmidt, H. et al. Gains in chromosomes 7, 8q, 15q and 17q are characteristic changes in malignant but not in benign peripheral nerve sheath tumors from patients with Recklinghausen's disease. Cancer Lett. 155, 181-190 (2000).
21. Schmidt, H. et al. Cytogenetic characterization of six malignant peripheral nerve sheath tumors: comparison of karyotyping and comparative genomic hybridization. Cancer Genet. Cytogenet. 128, 14-23 (2001).
22. Birindelli, S. et al. Rb and TP53 pathway alterations in sporadic and NF1- related malignant peripheral nerve sheath tumors. Lab. Invest. 81, 833-844 (2001).
23. Legius, E. et al. TP53 mutations are frequent in malignant NFI tumors. Genes Chromosom. Cancer 10, 250-255 (2006).
24. Perry, A. et al. Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J. Neuropathol. Exp. Neurol. 61, 702-709 (2002).
25. Menon, A.G. et al. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc. Natl. Acad. Sci. USA 87, 5435 (1990).
26. Kourea, H.P., Orlow, I., Scheithauer, B.W., Cordon-Cardo, C. & Woodruff, J.M. Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am. J. Pathol. 155, 1855 (1999).
27. Nielsen, G.P. et al. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am. J. Pathol. 155, 1879 (1999).
28. Mantripragada, K.K. et al. High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clin. Cancer Res. 14, 1015 (2008).
29. Mawrin, C. et al. Immunohistochemical and molecular analysis of p53, RB, and PTEN in malignant peripheral nerve sheath tumors. Virchows Arch. 440, 610-615 (2002).
30. Holtkamp, N. et al. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis 27, 664 (2006).
31. Storlazzi, C.T. et al. Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours. J. Pathol. 209, 492-500 (2006).
32. Badache, A. & De Vries, G.H. Neurofibrosarcoma-derived Schwann cells overexpress platelet-derived growth factor (PDGF) receptors and are induced to proliferate by PDGF BB. J. Cell. Physiol. 177, 334-342 (1998).
33. Badache, A., Muja, N. & De Vries, G.H. Expression of Kit in neurofibromin-deficient human Schwann cells: role in Schwann cell hyperplasia associated with type 1 neurofibromatosis. Oncogene 17, 795-800 (1998).
34. Keng, V.W. et al. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat. Biotechnol. 27, 264-274 (2009).
35. Dupuy, A.J. et al. A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. Cancer Res. 69, 8150-8156 (2009).
36. Wu, X. et al. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 482, 529-533 (2012).
37. Quintana, R.M. et al. A transposon-based analysis of gene mutations related to skin cancer development. J. Invest. Dermatol. 133, 239-248 (2013).
38. Lappe-Siefke, C. et al. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat. Genet. 33, 366-374 (2003).
39. Tabone-Eglinger, S. et al. Frequent EGFR positivity and overexpression in high-grade areas of human MPNSTs. Sarcoma 2008, 849156 (2008).
40. Holtkamp, N. et al. MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia 9, 671-677 (2007).
41. Ling, B.C. et al. Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell 7, 65-75 (2005).
42. de Vries, A. et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc. Natl. Acad. Sci. USA 99, 2948-2953 (2002).
43. Carli, M. et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J. Clin. Oncol. 23, 8422-8430 (2005).
44. Stucky, C.C.H. et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann. Surg. Oncol. 19, 878-885 (2012).
45. Pytel, P., Taxy, J.B. & Krausz, T. Divergent differentiation in malignant soft tissue neoplasms: the paradigm of liposarcoma and malignant peripheral nerve sheath tumor. Int. J. Surg. Pathol. 13, 19-28 (2005).
46. Magro, G. et al. Multinucleated floret-like giant cells in sporadic and NF1-associated neurofibromas: a clinicopathologic study of 94 cases. Virchows Arch. 456, 71-76 (2010).
47. Rodriguez, F.J., Folpe, A.L., Giannini, C. & Perry, A. Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol. 123, 295-319 (2012).
48. Collier, L.S., Carlson, C.M., Ravimohan, S., Dupuy, A.J. & Largaespada, D.A. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 436, 272-276 (2005).
49. Sarver, A.L., Erdman, J., Starr, T., Largaespada, D.A. & Silverstein, K.A. TAPDANCE: an automated tool to identify and annotate transposon insertion CISs and associations between CISs from next generation sequence data. BMC Bioinformatics 13, 154 (2012).
50. Brett, B.T. et al. Novel molecular and computational methods improve the accuracy of insertion site analysis in Sleeping Beauty-induced tumors. PLoS ONE 6, e24668 (2011).
51. Gregorian, C. et al. PTEN dosage is essential for neurofibroma development and malignant transformation. Proc. Natl. Acad. Sci. USA 106, 19479-19484 (2009).
52. Largaespada, D.A. & Collier, L.S. Transposon-mediated mutagenesis in somatic cells: identification of transposon-genomic DNA junctions. Methods Mol. Biol. 435, 95-108 (2008).
53. Feber, A. et al. Comparative methylome analysis of benign and malignant peripheral nerve sheath tumors. Genome Res. 21, 515-524 (2011).
54. Yang, J. et al. Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment. Clin. Cancer Res. 17, 7563-7573 (2011).
55. Forbes, S.A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-D950 (2011).
56. Ghadimi, M.P. et al. Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors. Mol. Cancer Ther. 11, 1758-1769 (2012).
57. Saito, T. et al. Nuclear β-catenin correlates with cyclin D1 expression in spindle and pleomorphic sarcomas but not in synovial sarcoma. Hum. Pathol. 37, 689-697 (2006).
58. Mo, W. et al. CXCR4/CXCL12 mediate autocrine cell-cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell 152, 1077-1090 (2013).
59. Keng, V.W. et al. PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors. Cancer Res. 72, 3405-3413 (2012).
60. Starr, T.K. et al. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 323, 1747-1750 (2009).
61. Jessen, K.R. Glial cells. Int. J. Biochem. Cell Biol. 36, 1861-1867 (2004).
62. Pérez-Mancera, P.A. et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 486, 266-270 (2012).
63. Subramanian, S. et al. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J. Pathol. 220, 58-70 (2010).
64. Je, E.M., An, C.H., Yoo, N.J. & Lee, S.H. Mutational analysis of PIK3CA, JAK2, BRAF, FOXL2, IDH1, AKT1 and EZH2 oncogenes in sarcomas. APMIS 120, 635-639 (2012).
65. Jacks, T. et al. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat. Genet. 7, 353-361 (1994).
66. Cichowski, K. et al. Mouse models of tumor development in neurofibromatosis type 1. Science 286, 2172-2176 (1999).
67. Zhu, Y., Ghosh, P., Charnay, P., Burns, D.K. & Parada, L.F. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296, 920-922 (2002).
68. Wu, J. et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell 13, 105-116 (2008).
69. Katoh, M. Identification and characterization of human FOXN6, mouse Foxn6, and rat Foxn6 genes in silico. Int. J. Oncol. 25, 219 (2004).
70. Santo, E.E. et al. Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. Oncogene 31, 1571-1581 (2012).
71. Uhlen, M. et al. Towards a knowledge-based human protein atlas. Nat. Biotechnol. 28, 1248-1250 (2010).
72. Rhodes, D.R. et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6, 1 (2004).
73. Rhodes, D.R. et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9, 166 (2007).
74. Myatt, S.S. & Lam, E.W.F. The emerging roles of forkhead box (Fox) proteins in cancer. Nat. Rev. Cancer 7, 847-859 (2007).
75. Stemmer-Rachamimov, A.O. et al. Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res. 64, 3718-3724 (2004).
76. Dai, M. et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 33, e175 (2005).
77. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc., B 57, 289-300 (1995).
78. Irizarry, R.A. et al. The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 41, 178-186 (2009).
79. Yang, J. et al. Deletion of the WWOX gene and frequent loss of its protein expression in human osteosarcoma. Cancer Lett. 291, 31-38 (2010).
80. Olshen, A.B., Venkatraman, E., Lucito, R. & Wigler, M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557-572 (2004).
81. van de Wiel, M.A. et al. CGHcall: calling aberrations for array CGH tumor profiles. Bioinformatics 23, 892-894 (2007).
82. Sun, W. et al. Integrated study of copy number states and genotype calls using high-density SNP arrays. Nucleic Acids Res. 37, 5365-5377 (2009).
83. DeRycke, M.S. et al. S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival. Am. J. Clin. Pathol. 132, 846-856 (2009).
84. Rizzardi, A.E. et al. Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn. Pathol. 7, 42 (2012).
85. Daniel, A.R., Faivre, E.J. & Lange, C.A. Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Mol. Endocrinol. 21, 2890-2906 (2007).
86. Cermak, T. et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 39, e82 (2011).
87. Wood, A.J. et al. Targeted genome editing across species using ZFNs and TALENs. Science 333, 307 (2011).
88. Mussolino, C. et al. A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res. 39, 9283-9293 (2011).
89. Miller, J.C. et al. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 29, 143-148 (2011).
90. Guschin, D.Y. et al. A rapid and general assay for monitoring endogenous gene modification. Methods Mol. Biol. 649, 247-256 (2010).
91. Doyon, Y. et al. Transient cold shock enhances zinc-finger nuclease-mediated gene disruption. Nat. Methods 7, 459-460 (2010).